RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) will highlight that the value of artificial intelligence in healthcare is measured not by technological complexity alone, but by its ability to give clinicians more time, patients better experiences, and health systems greater capacity to deliver specialized care.
Wk 73: The U.S. and Iran are very close to signing an initial peace framework. Foster Savings Accounts, The Octagon, War on Fraud, rising Truth and Peace.
Madrid, Spain, June 13, 2026 (GLOBE NEWSWIRE) -- A 2026 company-aligned overview of how the Glacier Breeze Portable AC is presented across official product materials, including its Twin Frost Jet design, evaporative cooling technology, cooling cartridge system, and key considerations for consumers before purchasing.
GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...
DUBLIN, Ireland, June 13, 2026 /CNW/ - Today, the Prime Minister, Mark Carney, met with the Taoiseach of Ireland, Micheál Martin, during his bilateral...
MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies , a global provider of IT solutions and services, today opened a...
MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies , a global provider of IT solutions and services, today opened a...
Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --
An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026
BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.
BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.